source
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…BioSpace · 1d ago↗ source
- Endpoints Weekly highlights search for Alzheimer’s ‘statin’, Arrowhead’s tau-lowering injectable and AI Day recapEndpoints Weekly released its latest edition, previewing several biotech stories including a quest for a “statin of Alzheimer’s” and new data on Arrowhead’s injectable therapy that reduces tau prot…
- Moderna’s stock soars after Phase 3 success of melanoma vaccine with Merck